InSure® ONE™ at-home-collection makes collection for colorectal cancer easier than ever. Your patients don’t have to handle stool and according to USMSTF annual FIT is more effective and less costly than stool DNA.
Predict response to EGFR-targeted immunotherapy in patients with metastatic colorectal cancer.
Our extensive GI pathology services from AmeriPath offer a wide array of solutions for your practice and extensive client support services .
Dr. Petras is Director of the AmeriPath Institute of Gastrointestinal Pathology and Digestive Disease. He has written two books, produced more than 20 book chapters, co-authored over 200 GI disease-related scientific publication articles, and has helped produce over 18 training modules on the treatment of specific cases of disease. In 2011 he was named to the U.S. News and World Report’s annual list of “Top Doctors.”
Colorectal Cancer (CRC) is the third most common cancer in the U.S., but the second leading cause of cancer-related deaths. Read Dr. Marshall’s insights on widespread screening and genetic profiling to combat the disease.
As part of our service, you can access patient education materials to address common patient questions about diseases and tests. After disclosing a diagnosis, you can provide our Patient Diagnostic Fact Sheets on colon and stomach cancer, and more.
Learn how recent advances in basic and clinical research have helped to further the understanding of diagnostics in colorectal cancer screening. We’re proud sponsors of this independently-developed continuing medical education.